University of North Carolina at Chapel Hill-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2023

  1. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

2019

  1. Breast cancer PAM50 signature: Correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

    BMC Genomics, Vol. 20, Núm. 1

2018

  1. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

    Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829

  2. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification

    Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852

2017

  1. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts

    Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657

2011

  1. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

    Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136